Memorandum

JDRF to fund Cam Med's development of bandage-like, lower-cost patch pump ("Evopump") for next-generation automated insulin delivery - February 26, 2018

JDRF recently announced a new “Industry Development and Discovery Partnership” with Cam Med to develop a miniaturized, lower-cost insulin pump for next-generation automated insulin delivery systems. The funding will be used towards further development of Cam Med’s Evopump, an ultra-thin, flexible, and bandage-like patch pump that leverages multiple drug reservoirs and electrochemically-actuated design. Neither financials nor timelines for development/clinical studies were disclosed in the press release.

We first saw the patch pump (3 x 3 x 0.2 inches at the time) at ATTD 2017. As of one year ago, Cam Med had won several competitions and secured $440,000 in non-dilutive funding. The three-day disposable pump uses a unique reservoir array and an electrolysis-driven system. It operates via a handheld controller and is expected to have reduced manufacturing costs. Evopump is capable of delivering multiple medications – perhaps it could be used in a bihormonal AID system, with some of the reservoirs filled with glucagon or even amylin.

At ATTD 2017, Cam Med reported ±2% accuracy 95% of the time from individual reservoirs, which it believes is more accurate than the current screw-driven pumps. The company still refers to itself on its website as being development stage. The JDRF funding serves as an early vote of confidence and should help push the early-stage platform ahead. There are many barriers to entry in patch pump, but among the biggest is extremely high quality manufacturing and scale. Can Cam Med make it happen, where others have struggled?

Cam Med joins EOFlow and SFC Fluidics in the latest of a slew of recently-announced JDRF partnerships aimed at stimulating development of novel patch pumps and more “all-in-one” automated insulin delivery devices. All three of these partnerships – announced within the past two months – have involved novel patch pumps. It’s great to see JDRF’s focus on reducing on-body device burden, which is clearly one of the next key frontiers in driving device adoption. While not stated in the press release, it’s possible this funding will be provided over a two-year period in line with the other two Industry Development and Discovery partnerships. 

 

-- by Maeve Serino, Brian Levine, Adam Brown, and Kelly Close